Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Stock Down 5.6 %

NASDAQ NERV opened at $2.21 on Thursday. Minerva Neurosciences has a twelve month low of $2.06 and a twelve month high of $13.49. The firm has a market capitalization of $15.45 million, a PE ratio of -5.02 and a beta of 0.11. The stock’s 50 day moving average is $2.38 and its 200 day moving average is $2.75.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.